U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q For the transition period from _____ to _____. Commission File Number 0000-08092 GT BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 94-1620407 (I.R.S. employer identification number) 9350 Wilshire Blvd. Suite 203 Beverly Hills, CA 90212 (Address of principal executive offices and zip code) (800) 304-9888 (Registrant's telephone number, includi ...

U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☑ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2020. ☐ For the transition period from to . Commission File Number 0-8092 GT BIOPHARMA, INC. (Exact name of small business issuer as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 94-1620407 (I.R.S. employer identification number) 9350 Wilshire Blvd. Suite 2 ...

Financial Position - The company has incurred an accumulated deficit of $567,332,000 through December 31, 2019[199]. - As of December 31, 2019, the company had cash and cash equivalents of $28,000[199]. - As of December 31, 2019, the company had cash and cash equivalents of $28,000 and raised $3.5 million through convertible debentures during the year[249]. - The company will need to raise an additional $15 million of capital in 2020 to finance existing operations and pay current liabilities[249]. - The company has no off-balance sheet arrangements as of December 31, 2019[260]. Revenue and Losses - The company has not generated any revenue from product sales and expects operating losses to continue in the foreseeable future[249]. - A loss of $20,463,000 was reported for the sale of GTB-004 in the year ended December 31, 2019[246]. - An additional impairment charge of $4,599,000 was reported for remaining projects during the year ended December 31, 2019, following the loss on the sale of GTB-004[247]. - The company has sustained operating losses since inception and expects such losses to continue over the foreseeable future[249]. Expenses - Research and development expenses for the year ended December 31, 2019, were $1.7 million, a decrease from $9.1 million in 2018, with expectations to increase to approximately $12 to $15 million in 2020 due to ongoing clinical trials[242]. - Selling, general and administrative expenses for the year ended December 31, 2019, were $9.7 million, down from $12.5 million in 2018, with future expenses anticipated to range between $1 and $2 million in the coming quarters[243]. - Interest expense decreased to $2.1 million for the year ended December 31, 2019, from $9.1 million in 2018, attributed to reduced non-cash amortization of debt issuance costs[248]. - The company anticipates cash utilization for selling, general, and administrative expenses to range between $1 million and $2 million in the coming quarters[249]. - Research and development costs totaled $1.7 million for the year ended December 31, 2018, which included non-cash compensation of $6.8 million[257]. Agreements and Collaborations - The company entered into a Securities Purchase Agreement on January 22, 2018, issuing senior convertible notes totaling $7,760,510, convertible at a price of $4.58 per share[211]. - The company received proceeds of $7,055,000 from the Securities Purchase Agreement after a 10% original issue discount[212]. - The company issued 10% Senior Convertible Debentures in an aggregate principal amount of $5,140,000 on August 2, 2018, convertible at a price of $2 per share[216]. - The company executed a clinical trial agreement in September 2019 for the GTB-3550 TriKE™ Phase I/II clinical trial targeting certain types of leukemia[209]. - The company has entered into a collaboration agreement with Cytovance® Biologics to develop a TriKE™ therapeutic for coronavirus treatment[210]. - The company has exclusive rights to develop and commercialize DT2219ARL (GTB-1550) for various human cancers under a license agreement with Dr. Vallera[207]. - The company has a co-development partnership with Altor BioScience Corporation for the clinical development of a novel TriKE fusion protein for cancer therapies[204]. - The company has a Sponsored Research Agreement with the University of Minnesota to determine toxicities and in vivo behavior in its TriKE technology[203]. Impairment and Asset Evaluation - The company recorded an intangible asset impairment charge of $228.5 million for the year ended December 31, 2018, related to CNS IPR&D assets, due to strategic shifts towards immuno-oncology development[244]. - The company evaluates indefinite lived intangible assets for impairment at least annually and records impairment losses when necessary[255]. Market Conditions - Inflation has not had a material adverse impact on the company's business or operating results during the periods presented[259].

U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☑ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2019. ☐ For the transition period from to . Commission File Number 0-8092 GT BIOPHARMA, INC. (Exact name of small business issuer as specified in its charter) Delaware 94-1620407 (State or other jurisdiction of incorporation or organization) (I.R.S. employer identification number) 9350 Wilshire Blvd. Sui ...

U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☑ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2019. ☐ For the transition period from to . Commission File Number 0-8092 GT BIOPHARMA, INC. (Exact name of small business issuer as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 94-1620407 (I.R.S. employer identification number) 9350 Wilshire Blvd. Suite 20 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 Commission File Number: 000-08092 GT BIOPHARMA, INC. (Exact name of Registrant as specified in its charter) (State of incorporation or organization) (I.R.S. Employer Identification No.) Delaware 94-1620407 310 N. Westlake Blvd. Suite 206 Westlake Village, CA 91362 (Address of principal executive offi ...